Clinical Trial Search

Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants

Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg

Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants

Primary: Overall Response Rate (Confirmed) — 1; 1 Participants

Primary: Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)…

Primary: Overall Survival — 13.43; 7.62 months

Primary: Number of Grade 3 or 4 Adverse Events, Highest Occurrence Per Participant — 1; 0; 0; 0 Adverse events

Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants

Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants

Primary: Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level — 1; 3; 0; 2 Participants

Primary: Part I: Objective Response Rate (ORR) of Single-agent Cediranib in Participants With Advanced Alveolar Soft Part Sarcoma (ASPS) — 0; 0; 0; 1 Participants

Primary: Objective Response Rate ( ORR ) — 5.6; 0.0; 0.0; 11.9 Percentage of Participants — p=0.0309

Primary: Number of Participants With an Objective Response — 0; 0; 0; 0 Participants

Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants

Primary: Percent Increase in Sestamibi Retention in the Liver as a Measure of P-glycoprotein Inhibition — 71.9 percent increase sestamibi retention

Primary: To Establish the Safety and Tolerability of Single-agent AZD1775 in Patients With Refractory Solid Tumors — 6; 4; 6; 3 Participants

Primary: Percentage of Patients Tolerating Re-escalated Dose of Sorafenib for 28 Days Without Dose Interruption or De-escalation for Toxicity — 11 Participants

Primary: Number of Participants Experienced Dose Limit Toxicities (DLT) — 0; 0 Participants

Primary: Non-progression Rate (NPR) at 18 Weeks — 26.8; 44.4; 29.6; 40.0 percentage of participants

Primary: Objective Response Rate — 0; 1 participants

Primary: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events — 100.0; 100.0; 100.0; 99.8 Percentage of…

Primary: Phase II: Clinical Benefit Rate

Primary: Phase 2: Response Rate of This Combination in Participants With Colon Cancer, Non-small Cell Lung Cancer (NSCLC), and Granulosa Cell Ovarian Cancer — 0; 0; 0; 1…

Primary: Number of Participants With Adverse Events (AEs), and Serious Adverse Events (SAEs). — 11; 3 Participants

Primary: Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy — 5; 5; 5; 5 mg BID

Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1; 2 Participants

Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants

Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants

Primary: Total Cisplatin Pharmacokinetics (PK): Area Under the Concentration (AUC) Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) — 324; 338 micrograms*hour/milliliters…

Primary: Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration — 0; 0; 0; 0 Number of DLTs